A Moderate Response to Plasmapheresis in Nephrogenic Systemic Fibrosis

Nephrogenic systemic fibrosis (NSF) is a recently identified idiopathic cutaneous fibrosing disorder that occurs in the setting of renal failure. The disease initially called nephrogenic fibrosing dermopathy is closely linked to exposure to gadolinium-based contrast media used during magnetic resonance imaging in patients with renal insufficiency. Although little is known about the pathogenesis of this disease, the increased expression of transforming growth factor-beta has been demonstrated recently. Herein, we present a case of NSF was partially treated due to a moderate and temporary response to plasmapheresis with no recurrence for 6 months, but returned at the end of 6th month

Clinical and Histopathologic Differential Diagnosis of Venous Malformation of the Uterine Cervix

Ustuner, Isik/0000-0002-3791-4071; GUCER, HASAN/0000-0002-9122-379XWOS: 000330369100006PubMed: 23609595Objective. Venous malformations of the uterine cervix are extremely rare. Most lesions are asymptomatic and incidental, but sometimes, they may present with abnormal and/or intractable vaginal bleeding. the study aimed to describe a case of venous malformation of the uterine cervix and discuss the clinical and histopathologic differential diagnosis of this entity. Case. A 50-year-old woman attended to the gynecology clinic for postcoital spotting and postmenopausal bleeding. Gynecologic examination revealed polypoid, lobulated, bluish, vascular nodular lesions 4 to 1 cm in size surrounding the cervical introitus. the lesions were completely excised via loop electrosurgical excision procedure method. Pathologic diagnosis revealed venous malformations of the uterine cervix. Conclusions. Venous malformations of the uterine cervix should be considered in the differential diagnosis of patients with cervical mass and vaginal bleeding. Pathologic examination is necessary in such a case to exclude the possibility ofmalignant vascular tumor or cervical neoplasm

Low Dose Methotrexate Induced Perilesional Bullous Erythema in Plaque Type Psoriasis

WOS: 000396411700013The bullous variant of chemotherapy-induced acral erythema has been reported with methotrexate and more frequently cytosine arabinoside. However, perilesional bullous erythema in association with methotrexate hasn't been reported before. Herein, we presented a 64-year-old male patient, a biopsy proven case of generalized plaque psoriasis, who developed a bullous perilesional erythema after a single oral dose of 15 mg/week methotrexate. the patient developed symmetrical, well-demarcated, painful, erythematous perilesional bullous lesions surrounding these psoriasiform plaques within 3 days of receiving the medication. the lesions were unresponsive to the potent topical corticosteroids and wet dressings. After 3 weeks the topical corticosteroids were discontinued and methotrexate dose was reduced to 10 mg/week. As a result of the permanency of the bullous perilesional erythema, a topical herbal therapy including a henna extract "Lawsonia inermis" was started for an anti-inflammatory response. the lesions gradually improved and resolved almost completely with residual hyperpigmentation within two weeks. We believe that, perilesional bullous erythema may be seen rarely in psoriatic patients treated with methotrexate and there is no need for discontinuation of methotrexate therapy

The efficacy of adalimumab in the treatment of hidradenitis suppurativa

Objectives:Hidraadenitissuppurativa is seen as a result of the occlusion, constriction and bacterial infection of the apocrine glands in bilateral axillas, submammarian areas, neck, inguinal regions, flexural surfaces of the thighs and anogenital areas. Among the biological agents adalimumab is a recombinant human IgG1 monoclonal antibody; TNF-α antagonist approved to be used in the treatment of hidradenitissuppurativa. Methods: In this study, 12 patients resistant to conventional treatments with moderate severity, Hurley stage 2 or 3 were started subcutaneous adalimumab treatment. The disease activities upon the hidraadenitissuppurativa, clinical severity index and life quality index of the patients were examined both before and 1 year after the treatment. Results: Twelve patients were recruited. In the examination of the hidraadenitissuppurativa clinical severity scores, significant clinical responses were noted in 9 (75%) patients. While the mean value of the life quality index was 14.4±6.9 before the treatment, it was determined to be significantly decreased to 4.3±3.8 after the treatment. Conclusion: We concluded that adalimumab; the unique biological agent approved to be used in the treatment of treatment-resistant, moderate-severe hidraadenitissuppurativa is efficient and safe in similar ratios with the previous clinical studies in the literature

A moderate response to plasmapheresis in nephrogenic systemic fibrosis

Nephrogenic systemic fibrosis (NSF) is a recently identified idiopathic cutaneous fibrosing disorder that occurs in the setting of renal failure. The disease initially called nephrogenic fibrosing dermopathy is closely linked to exposure to gadolinium-based contrast media used during magnetic resonance imaging in patients with renal insufficiency. Although little is known about the pathogenesis of this disease, the increased expression of transforming growth factor-beta has been demonstrated recently. Herein, we present a case of NSF was partially treated due to a moderate and temporary response to plasmapheresis with no recurrence for 6 months, but returned at the end of 6th month